CYP17A1 and ovarian cancer: Many previous studies have linked CYP17 polymorphisms to the risk of breast cancer, endometrial cancer, ovarian cancer, uterine fibroids, endometriosis, recurrent miscarriage, and ICP (He et al., 2022; Zhang et al., 2006a).